Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

Core Viewpoint - Capricor Therapeutics, Inc. has announced a public offering of 6,000,000 shares of common stock priced at $25.00 per share, aiming to raise approximately $150 million in gross proceeds to support its product development and general corporate purposes [1][2][3]. Group 1: Offering Details - The public offering consists of 6,000,000 shares at a price of $25.00 per share, with an additional 900,000 shares available for underwriters to purchase within 30 days [1] - The offering is expected to close around December 8, 2025, pending customary closing conditions [1] - Piper Sandler and Oppenheimer & Co. are the joint book-running managers, while H.C. Wainwright & Co. serves as the co-manager for the offering [2] Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for the continued development and manufacturing of product candidates, working capital, and general corporate purposes [3] Group 3: Company Overview - Capricor Therapeutics focuses on developing cell and exosome-based therapeutics, with its lead product candidate, Deramiocel, in late-stage clinical development for Duchenne muscular dystrophy (DMD) [6] - Deramiocel has shown significant immunomodulatory and anti-fibrotic effects in preserving cardiac and skeletal muscle function in DMD patients [6] - The company is also advancing its proprietary StealthX™ platform for targeted delivery of therapeutics, with applications in vaccinology and treatment of various diseases [6] Group 4: Regulatory and Commercialization - The offering is conducted under an effective shelf registration statement filed with the SEC, ensuring compliance with regulatory requirements [4] - Capricor has an exclusive agreement with Nippon Shinyaku Co., Ltd. for the commercialization and distribution of Deramiocel in the U.S. and Japan, pending regulatory approval [9]